key: cord-0937908-4r5969gq authors: Wang, Vivian; Boguniewicz, Juri; Boguniewicz, Mark; Ong, Peck Y. title: The Infectious Complications of Atopic Dermatitis date: 2020-08-07 journal: Ann Allergy Asthma Immunol DOI: 10.1016/j.anai.2020.08.002 sha: 6d55f5f71160cc745addfa339cd4951ff0702305 doc_id: 937908 cord_uid: 4r5969gq OBJECTIVE: Atopic dermatitis (AD) is a chronic inflammatory skin disease that is complicated by an increased risk for skin and systemic infections. Preventive therapy for AD is based on skin barrier improvement and anti-inflammatory treatments, whereas overt skin and systemic infections require antibiotics or anti-viral treatments. This review updates the pathophysiology, diagnosis, management, controversy of antibiotic use, and potential treatments of AD infectious complications. DATA SOURCES: Published literature obtained through PubMed searches and clinical pictures. STUDY SELECTIONS: Studies relevant to the mechanisms, diagnosis, management and potential therapy of AD infectious complications. RESULTS: Skin barrier defects, type 2 inflammation, S. aureus colonization and cutaneous dysbiosis are the major predisposing factors for the increased infections in AD. While overt infections require antibiotics, the use of antibiotics in AD exacerbation remains controversial. CONCLUSION: Infectious complications are a co-morbidity of AD. Although not common, systemic bacterial infections and eczema herpeticum can be life-threatening. Preventive therapy of infections in AD emphasizes skin barrier improvement and anti- inflammatory therapy. The use of antibiotics in AD exacerbation requires further studies. with severe AD exacerbation who may benefit from antibiotics in terms of infections or 134 prevention of infectious complications. 4, 28, 29 It has been proposed that these patients may be 135 differentiated by a higher density of S. aureus and amount of tissue damage caused by S. aureus- 136 host interaction. 29 Children with severe AD exacerbation were found to have elevated CRP and 137 ESR, although these levels were significantly less than that of patients with infectious 138 complications. 4 There may be potential use in these inflammatory markers in identifying AD 139 patients who are at risk for severe infectious complications. hospitalized for AD infectious complications were related to EH. 4 Younger age and non-white 145 race (African Americans, Asians, and Native Americans) are at increased risk for hospitalization 146 with EH. 30 HSV exposure is common in the general population and is present in 60% of adults and 152 20% of children. 31 Immunologic and genetic elements likely contribute to the vulnerability of a 153 subset of AD patients, as EH only affects 3% of AD patients. 31 mouth disease such as oral sores and papules involving hands and feet (Fig. 4) . Other possible 165 symptoms include fever, sore throat and poor appetite. In contrast to EH, EC is not life-166 threatening and can be managed with standard AD treatments. 2 If the diagnosis between EH and 167 EC is unclear, a lesional PCR for enterovirus can be obtained to differentiate between the two 168 etiologies. Though more common in children, EC has also been described in adults. 32 Molluscum contagiosum (MC) is a poxvirus that belongs to the Molluscipoxvirus 170 subfamily, but it is distinct from vaccinia, variola, and cowpox viruses in the Orthopoxvirinae 171 genus. 33 MC infection in AD patients may be diffuse or along the AD distribution ( live vaccinia virus (VV) in smallpox vaccines. 2 EV is rare since the discontinuation of routine 11 acid (apple cider vinegar) has been used as a antimicrobial bathing additive for AD, 52 although 225 its efficacy in S. aureus clearance in AD has not been established. Another study showed that 226 0.5% acetic acid daily bath for 14 days did not improve skin barrier function or acidity in AD 227 patients, as compared to plain water baths. 53 On the other hand, skin irritation was reported in 228 some patients treated with dilute acetic acid. Chlorhexidine bath has been used in the 229 decolonization of MRSA in the general population, but it has not been studied adequately in AD. A potential side effect of this antimicrobial agent is allergic contact dermatitis. 54 The Infectious 231 Diseases Society of America published guidelines for the management of recurrent SSTI due to 232 MRSA in 2011. 55 Similar principles apply to the management of recurrent SSTI in AD. Based 233 on these guidelines and findings of more recent studies/expert opinion, a suggested approach to 234 decolonization of S. aureus in AD patients with recurrent SSTIs is outlined in Table 1 . 55 results. Clindamycin can also be considered if there is not concern for an endovascular infection 246 and local prevalence of clindamycin resistance is <15%. 58 assuming the isolate is susceptible in-vitro. 55 Of note, the rates of clindamycin resistance have 263 been rising amongst both MRSA and MSSA nationally, though there is regional variation. 59 Mechanisms of S. aureus transmission (e.g. skin-to-skin contact, fomites) Emphasize personal hygiene practices: Frequent hand washing with soap and water or alcohol-based sanitizer Daily bathing or showering Avoid reusing or sharing personal hygiene items that contact the skin (e.g. towels, loofas, razors, cosmetics, brushes, etc.) Avoid contamination of topical medications and moisturizers (use pump or pour containers) Keep fingernails clean and trimmed, avoid scratching Regularly clean high-touch surfaces (e.g. counters, door knobs, appliances, etc.) with commercially available disinfectants Use a barrier between exposed skin and high-touch surfaces touched by multiple people (e.g. exercise equipment) Wash clothing, towels and washcloths with hot water and detergent before reuse Wash bedding at onset and completion of decolonization regimen Wash hands before and after touching pets Nasal decolonization with intranasal mupirocin 2% ointment twice daily for 5-10 days AND Topical decolonization with either one of the following: Dilute bleach baths a for 15 minutes twice weekly (1 tsp of bleach per gallon of water or ¼ cup of bleach per ¼ standard tub or 13 gallons of water) for 3 months Chlorhexidine gluconate 4% solution b once daily for 5-14 days Dilute bleach baths for 15 minutes twice weekly with chlorhexidine washes daily on days bleach baths not given for 3 months Optimize underlying condition, personal and environmental hygiene Assess level of adherence with above regimen Repeat decolonization of patient and all household contacts with: Intranasal mupirocin 2% ointment twice daily for 5 days once or twice a month for 6 months AND Topical decolonization with dilute bleach baths as above twice weekly OR chlorhexidine gluconate solution as above for 5 days every 2 weeks for 6 months c May consider concomitant use of oral antibiotic therapy on a case-by-case basis with rifampin and another oral agent to which the isolate is susceptible to for 5-10 days J o u r n a l P r e -p r o o f a Dilute bleach baths may be preferable to chlorhexidine solutions in AD patients as chlorhexidine can cause skin irritation, repeat exposure can lead to resistance and it is more costly. b Chlorhexidine can be applied as a wash or disposable wipe, care should be taken to avoid the contact with the face and the 4% solution should be thoroughly rinsed off with water after application. c Can consider changing decolonizing agents. J o u r n a l P r e -p r o o f Insights From Caregivers on the Impact of Pediatric Atopic Dermatitis on Families: "I'm Tired, Overwhelmed, and Feel Like I'm Failing as a Mother Bacterial and Viral Infections in Atopic Dermatitis: a Comprehensive Review Association between atopic dermatitis and serious cutaneous, multiorgan and systemic infections in US adults Antibiotic choice and methicillin-resistant Staphylococcus aureus rate in children hospitalized for atopic dermatitis Economic burden of cutaneous infections in children and adults with atopic dermatitis The relationship of transepidermal water loss to skin temperature in psoriasis and eczema Does moisturizing the skin equate with barrier repair therapy? Stratum corneum pH in atopic dermatitis: impact on skin barrier function and colonization with Staphylococcus Aureus Correlation of age-of-onset of Atopic Dermatitis with Filaggrin loss-of-function variant status Association of Filaggrin Loss-of-Function Variants With Race in Children With Atopic Dermatitis Lipid abnormalities in atopic skin are driven by type 2 cytokines Innate lymphoid cells and allergic disease Endogenous antimicrobial peptides and skin infections in atopic dermatitis ILC2s and Basophils Team Up to Orchestrate IL-33-Induced Atopic Dermatitis ILC2 activation by keratinocyte-derived IL-25 drives IL-13 production at sites of allergic skin inflammation Langerhans and inflammatory dendritic epidermal cells in atopic dermatitis are tolerized toward TLR2 activation Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis Microbe-host interplay in atopic dermatitis and psoriasis Interactions Between Atopic Dermatitis and Staphylococcus aureus Infection: Clinical Implications Staphylococcal enterotoxins modulate the effector CD4 + T cell response by reshaping the gene expression profile in adults with atopic dermatitis Staphylococcus aureus enterotoxins modulate IL-22-secreting cells in adults with atopic dermatitis The role of the skin microbiome in atopic dermatitis Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the Infectious Diseases Society of America Trends in the incidence of methicillinresistant Staphylococcus aureus infection in children's hospitals in the United States Punched-out erosions with scalloped borders: Group A Streptococcal pustulosis Oral and Topical Antibiotics for Clinically Infected Eczema in Children: A Pragmatic Randomized Controlled Trial in Ambulatory Care Interventions to reduce Staphylococcus aureus in the management of eczema Antimicrobial resistance in atopic dermatitis: Need for an urgent rethink The role of bacterial skin infections in atopic dermatitis: expert statement and review from the International Eczema Council Skin Infection Group Epidemiology of Eczema Herpeticum in Hospitalized U.S. Children: Analysis of a Nationwide Cohort Why is eczema herpeticum unexpectedly rare? Atypical hand, foot, and mouth disease: Eczema coxsackium can also occur in adults Viral infections in atopic dermatitis: pathogenic aspects and clinical management Filaggrin mutations and Molluscum contagiosum skin infection in patients with atopic dermatitis Transmission of vaccinia virus, possibly through sexual contact, to a woman at high risk for adverse complications Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape Petrolatum: Barrier repair and antimicrobial responses underlying this "inert" moisturizer Effects of a novel formulation of fluocinonide 0.1% cream on skin barrier function in atopic dermatitis Comparison of effects of tacrolimus ointment and mometasone furoate cream on the epidermal barrier of patients with atopic dermatitis Effects of pimecrolimus compared with triamcinolone acetonide cream on skin barrier structure in atopic dermatitis: a randomized, double-blind, right-left arm trial Topical corticosteroids and Staphylococcus aureus in atopic dermatitis Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (Fk506) Staphylococcus colonization in atopic dermatitis treated with fluticasone or tacrolimus with or without antibiotics Skin colonization by Staphylococcus aureus in patients with eczema and atopic dermatitis and relevant combined topical therapy: a double-blind multicentre randomized controlled trial Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis Cutaneous microbiome effects of fluticasone propionate cream and adjunctive bleach baths in childhood atopic dermatitis Recurrent eczema herpeticum -a retrospective European multicenter study evaluating the clinical characteristics of eczema herpeticum cases in atopic dermatitis patients IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials Dilute bleach baths used for treatment of atopic dermatitis are not antimicrobial in vitro Comparison of bleach, acetic acid, and other topical anti-infective treatments in pediatric atopic dermatitis: A retrospective cohort study on antibiotic exposure Apple cider vinegar soaks [0.5%] as a treatment for atopic dermatitis do not improve skin barrier integrity Allergic contact dermatitis to chlorhexidine in pediatric patients Clinical practice guidelines by the Infectious Disease Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary Environmental Methicillin-resistant Staphylococcus aureus Contamination, Persistent Colonization, and Subsequent Skin and Soft Tissue Infection Prevention Strategies for Recurrent Community-Associated Staphylococcus aureus Skin and Soft Tissue Infections Report of the Committee of Infectious Diseases 31 st ed Changing Susceptibility of Staphylococcus aureus in a US Pediatric Population Treatment of eczema herpeticum with oral acyclovir The clinical spectrum and therapeutic challenge of eczema herpeticum Beetle juice: a guide for the use of cantharidin in the treatment of molluscum contagiosum Safety and efficacy of topical cantharidin for the treatment of pediatric molluscum contagiosum: a prospective, randomized, double-blind, placebo-controlled pilot trial New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines Efficacy and safety of PAC-14028 cream -a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial Outside-in hypothesis revisited: the role of microbial, epithelial and immune interactions Emollients for prevention of atopic dermatitis in infancy A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitis Targeting the Cutaneous Microbiota in Atopic Dermatitis by Coal Tar via AHR-Dependent Induction of Antimicrobial Peptides Rosmarinus officinalis L. (Rosemary) Extracts Containing Carnosic Acid and Carnosol are Potent Quorum Sensing Inhibitors of Staphylococcus aureus Virulence Pharmacodynamic Effects of Topical Omiganan in Patients With Mild to Moderate Atopic Dermatitis in a Phase II Trial Exebacase for patients with Staphylococcus aureus bloodstream infection and endocarditis Development of a vaccine against Staphylococcus aureus invasive infections: Evidence based on human immunity, genetics and bacterial evasion mechanisms First-in-human topical microbiome transplantation with Roseomonas mucosa for atopic dermatitis Quorum sensing between bacterial species on the skin protects against epidermal injury in atopic dermatitis